董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Simard | 男 | Chairman of the Board and Director | 64 | 3013.42万美元 | 567.17 | 2026-11-24 |
| Thomas Kündig | 男 | Independent Director | 63 | 20.29万美元 | 37.91 | 2026-11-24 |
| Craig Rademaker | 男 | Independent Director | 61 | 23.64万美元 | 26.31 | 2026-11-24 |
| Tevi D. Troy | 男 | Independent Director | 59 | 13.32万美元 | 5.60 | 2026-11-24 |
| David Soffer | 男 | Independent Director | 61 | 12.09万美元 | 5.10 | 2026-11-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sushma Shivaswamy | 女 | Chief Scientific Officer and Interim Chief Executive Officer | 48 | 57.10万美元 | 51.50 | 2026-11-24 |
| Angela Hu | 女 | Director of Finance | 43 | 24.54万美元 | 8.05 | 2026-11-24 |
董事简历
中英对照 | 中文 | 英文- John Simard
-
John Simard是XBiotech的创始人兼首席执行官。加入XBiotech前，他是CTL ImmunoTherapies Corp.的创始人兼首席执行官，这是一家治疗癌症和慢性传染病治疗疫苗的开发商；他还创立了加利福尼亚州巴伦西亚的AlleCure Corp.，这是一家过敏症治疗和免疫调节疗法的开发商。AlleCure和CTL ImmunoTherapies于2001年合并成立MannKind Corp.，Simard先生在该公司担任公司副总裁兼董事。Simard先生在萨斯喀彻温大学（University of Saskatchewan）获得生物化学学位；在多伦多大学（University of Toronto）就读医疗生物物理学与免疫学硕士课程。他拥有超过140项已发行和申请中的专利，这些专利与癌症治疗、治疗疫苗和治疗性抗体有关，他叫发表过大量的专家评审科学出版物和教材《免疫反应基因》。
John Simard Chairman of the Board, founded XBiotech Inc. in 2005 and served as its President and Chief Executive Officer and Chairman of the Board from 2005 to 2025. He retired from his role as President and Chief Executive Officer effective December 8, 2025 and continues to serve as Chairman of the Board of Directors and as a Scientific Advisor. Prior to XBiotech, he was founder and Chief Executive Officer of CTL ImmunoTherapies Corp., a developer of therapeutic vaccines to treat cancer and chronic infectious disease; he also founded AlleCure Corp., of Valencia, California, a developer of allergy treatments and immune modulating therapies. In 2001, AlleCure and CTL ImmunoTherapies merged to form MannKind Corp., where Mr. Simard served as Corporate Vice President and a board member. Mr. Simard holds a degree in Biochemistry from the University of Saskatchewan and attended graduate studies in Medical Biophysics/Immunology at the University of Toronto. He has over 240 issued and pending patents related to cancer therapy, therapeutic vaccines and therapeutic antibodies, as well as a substantial number of peer reviewed scientific publications and the textbook "Immune Response Genes". - John Simard是XBiotech的创始人兼首席执行官。加入XBiotech前，他是CTL ImmunoTherapies Corp.的创始人兼首席执行官，这是一家治疗癌症和慢性传染病治疗疫苗的开发商；他还创立了加利福尼亚州巴伦西亚的AlleCure Corp.，这是一家过敏症治疗和免疫调节疗法的开发商。AlleCure和CTL ImmunoTherapies于2001年合并成立MannKind Corp.，Simard先生在该公司担任公司副总裁兼董事。Simard先生在萨斯喀彻温大学（University of Saskatchewan）获得生物化学学位；在多伦多大学（University of Toronto）就读医疗生物物理学与免疫学硕士课程。他拥有超过140项已发行和申请中的专利，这些专利与癌症治疗、治疗疫苗和治疗性抗体有关，他叫发表过大量的专家评审科学出版物和教材《免疫反应基因》。
- John Simard Chairman of the Board, founded XBiotech Inc. in 2005 and served as its President and Chief Executive Officer and Chairman of the Board from 2005 to 2025. He retired from his role as President and Chief Executive Officer effective December 8, 2025 and continues to serve as Chairman of the Board of Directors and as a Scientific Advisor. Prior to XBiotech, he was founder and Chief Executive Officer of CTL ImmunoTherapies Corp., a developer of therapeutic vaccines to treat cancer and chronic infectious disease; he also founded AlleCure Corp., of Valencia, California, a developer of allergy treatments and immune modulating therapies. In 2001, AlleCure and CTL ImmunoTherapies merged to form MannKind Corp., where Mr. Simard served as Corporate Vice President and a board member. Mr. Simard holds a degree in Biochemistry from the University of Saskatchewan and attended graduate studies in Medical Biophysics/Immunology at the University of Toronto. He has over 240 issued and pending patents related to cancer therapy, therapeutic vaccines and therapeutic antibodies, as well as a substantial number of peer reviewed scientific publications and the textbook "Immune Response Genes".
- Thomas Kündig
-
Thomas K ü ndig于2025年6月24日被任命为公司董事会成员。K ü ndig博士是学术医学领域的杰出领导者，目前担任苏黎世大学医院（USZ）皮肤科主任和苏黎世大学皮肤病学正教授。K ü ndig博士的职业生涯以对免疫血液学的开创性贡献为标志，特别是在开发淋巴内免疫疗法（ILIT）方面，该疗法显着缩短了过敏患者的治疗时间。他的研究小组还提出了癌症免疫疗法和过敏原特异性单克隆抗体的临床前模型。作为部门主管，K ü ndig博士监督了大量资源和复杂的临床操作，领导了以患者为中心的护理举措，包括整合自助项目以提高健康素养。他的领导将USZ的皮肤科诊所定位为国家和国际参考中心，这反映了他提升机构绩效和声誉的能力。K ü ndig的治理经验包括在瑞士皮肤病与性病学学会和欧洲皮肤病学论坛担任董事会职务。此外，他还获得了瑞士技术奖和格奥尔格·弗里德里希·戈兹奖。K ü ndig教授拥有苏黎世大学的医学博士学位。
Thomas Kündig was appointed to the Company's Board of Directors on June 24, 2025. Dr. Kündig is a distinguished leader in academic medicine, currently serving as Director of the Department of Dermatology at the University Hospital Zurich (USZ) and Full Professor of Dermatology at the University of Zurich. Dr. Kündig's career is marked by pioneering contributions to immunohematology, particularly in the development of intralymphatic immunotherapy (ILIT), which has significantly reduced treatment durations for allergy patients. His research group has also advanced preclinical models for cancer immunotherapy and allergen specific monoclonal antibodies. As a department head, Dr. Kündig has overseen substantial resources and complex clinical operations, leading initiatives in patient centered care, including the integration of self help programs to enhance health literacy. His leadership has positioned USZ's dermatology clinic as a national and international reference center, reflecting his ability to elevate institutional performance and reputation.Dr. Kündig's governance experience includes board roles in the Swiss Society for Dermatology & Venereology and the European Dermatology Forum. As well, he is a recipient of the Swiss Technology Award and the Georg Friedrich Gotz Prize. Prof. Kündig has an M.D. from the University of Zürich. - Thomas K ü ndig于2025年6月24日被任命为公司董事会成员。K ü ndig博士是学术医学领域的杰出领导者，目前担任苏黎世大学医院（USZ）皮肤科主任和苏黎世大学皮肤病学正教授。K ü ndig博士的职业生涯以对免疫血液学的开创性贡献为标志，特别是在开发淋巴内免疫疗法（ILIT）方面，该疗法显着缩短了过敏患者的治疗时间。他的研究小组还提出了癌症免疫疗法和过敏原特异性单克隆抗体的临床前模型。作为部门主管，K ü ndig博士监督了大量资源和复杂的临床操作，领导了以患者为中心的护理举措，包括整合自助项目以提高健康素养。他的领导将USZ的皮肤科诊所定位为国家和国际参考中心，这反映了他提升机构绩效和声誉的能力。K ü ndig的治理经验包括在瑞士皮肤病与性病学学会和欧洲皮肤病学论坛担任董事会职务。此外，他还获得了瑞士技术奖和格奥尔格·弗里德里希·戈兹奖。K ü ndig教授拥有苏黎世大学的医学博士学位。
- Thomas Kündig was appointed to the Company's Board of Directors on June 24, 2025. Dr. Kündig is a distinguished leader in academic medicine, currently serving as Director of the Department of Dermatology at the University Hospital Zurich (USZ) and Full Professor of Dermatology at the University of Zurich. Dr. Kündig's career is marked by pioneering contributions to immunohematology, particularly in the development of intralymphatic immunotherapy (ILIT), which has significantly reduced treatment durations for allergy patients. His research group has also advanced preclinical models for cancer immunotherapy and allergen specific monoclonal antibodies. As a department head, Dr. Kündig has overseen substantial resources and complex clinical operations, leading initiatives in patient centered care, including the integration of self help programs to enhance health literacy. His leadership has positioned USZ's dermatology clinic as a national and international reference center, reflecting his ability to elevate institutional performance and reputation.Dr. Kündig's governance experience includes board roles in the Swiss Society for Dermatology & Venereology and the European Dermatology Forum. As well, he is a recipient of the Swiss Technology Award and the Georg Friedrich Gotz Prize. Prof. Kündig has an M.D. from the University of Zürich.
- Craig Rademaker
-
Craig Rademaker于2025年6月24日被任命为公司董事会成员。Rademaker先生在金融行业拥有超过35年的经验，涉及众多领域和行业，包括私营和公共部门。其中包括机构和零售经纪、本金交易、股权和债务筹集、并购建议以及作为促进者和主要投资者的风险投资。Rademaker先生16岁开始了他的风险投资生涯，在他父亲位于不列颠哥伦比亚省温哥华的公司工作。23岁时，Rademaker先生开始在交易部门工作，并迅速晋升为承销集团，管理一个国际贸易部门，专注于上市公司的交易波动性和做市。在承销期间，Rademaker先生负责与美国、加拿大和国际交易所相关的多次首次公开募股、反向收购和合并。在从事了大约15年20年的承销工作后，拉德梅克先生转型成为资本市场的领导者。他曾担任多家加拿大私募股权公司的顾问，并为一家欧洲信托公司集团开设了加拿大办事处。Rademaker先生的重点已经演变为帮助公司和投资者制定风险缓解策略、调整竞争利益和完善资本存量。Rademaker先生拥有Simon Fraser大学经济学理学学士学位。
Craig Rademaker was appointed to the Company's Board of Directors on June 24, 2025. Mr. Rademaker has over 35 years' experience in the financial industry, covering a multitude of areas and industries, both private and public. These include institutional and retail brokerage, principal trading, equity and debt raising, mergers and acquisitions advice and venture capital as a facilitator and principal investor. Mr. Rademaker started his career in venture capital at the age of 16, working in his father's firm in Vancouver, B.C. At 23 Mr. Rademaker began working on the trade desk and was quickly promoted to the underwriting group, managing an international trade desk with focus on trading volatility and market making for public companies. During his underwriting years, Mr. Rademaker was responsible for multiple initial public offerings, reverse take overs and mergers related to US, Canadian and international exchanges. After approximately 15 20 years in underwriting, Mr. Rademaker transitioned to become a capital markets leader. He has served as a consultant to multiple Canadian private equity firms and opened a Canadian office for a European trust company group. Mr. Rademaker' focus has evolved towards helping companies and investors build risk mitigating strategies, align compete interests and perfect capital stocks. Mr. Rademaker has a B.Sc. degree in economics from Simon Fraser University. - Craig Rademaker于2025年6月24日被任命为公司董事会成员。Rademaker先生在金融行业拥有超过35年的经验，涉及众多领域和行业，包括私营和公共部门。其中包括机构和零售经纪、本金交易、股权和债务筹集、并购建议以及作为促进者和主要投资者的风险投资。Rademaker先生16岁开始了他的风险投资生涯，在他父亲位于不列颠哥伦比亚省温哥华的公司工作。23岁时，Rademaker先生开始在交易部门工作，并迅速晋升为承销集团，管理一个国际贸易部门，专注于上市公司的交易波动性和做市。在承销期间，Rademaker先生负责与美国、加拿大和国际交易所相关的多次首次公开募股、反向收购和合并。在从事了大约15年20年的承销工作后，拉德梅克先生转型成为资本市场的领导者。他曾担任多家加拿大私募股权公司的顾问，并为一家欧洲信托公司集团开设了加拿大办事处。Rademaker先生的重点已经演变为帮助公司和投资者制定风险缓解策略、调整竞争利益和完善资本存量。Rademaker先生拥有Simon Fraser大学经济学理学学士学位。
- Craig Rademaker was appointed to the Company's Board of Directors on June 24, 2025. Mr. Rademaker has over 35 years' experience in the financial industry, covering a multitude of areas and industries, both private and public. These include institutional and retail brokerage, principal trading, equity and debt raising, mergers and acquisitions advice and venture capital as a facilitator and principal investor. Mr. Rademaker started his career in venture capital at the age of 16, working in his father's firm in Vancouver, B.C. At 23 Mr. Rademaker began working on the trade desk and was quickly promoted to the underwriting group, managing an international trade desk with focus on trading volatility and market making for public companies. During his underwriting years, Mr. Rademaker was responsible for multiple initial public offerings, reverse take overs and mergers related to US, Canadian and international exchanges. After approximately 15 20 years in underwriting, Mr. Rademaker transitioned to become a capital markets leader. He has served as a consultant to multiple Canadian private equity firms and opened a Canadian office for a European trust company group. Mr. Rademaker' focus has evolved towards helping companies and investors build risk mitigating strategies, align compete interests and perfect capital stocks. Mr. Rademaker has a B.Sc. degree in economics from Simon Fraser University.
- Tevi D. Troy
-
特维·D·特洛伊是罗纳德·里根研究所的高级研究员、叶史瓦大学施特劳斯中心的高级学者、前白宫助手和总统历史上最畅销的作家。特洛伊博士是美国卫生与公众服务部前副部长，联邦政府最大文职部门的首席运营官，预算7160亿美元，雇员超过6.7万人。特洛伊博士拥有丰富的白宫经验，曾担任多个高级职位，最终担任副助理，然后是总统国内政策代理助理。特洛伊博士也曾在国会山担任过高级职务，曾担任参议员约翰·阿什克罗夫特的政策主管，高级国内政策顾问，后来担任众议院政策委员会的国内政策主管。除了政府工作和医疗保健方面的专业知识外，特洛伊博士还为纽约时报、华尔街日报、华盛顿邮报、Politico、大西洋和许多其他出版物撰写了400多篇已发表的文章。他经常担任电视和电台分析师，曾在CNN、C SPAN、福克斯新闻、NewsHour等媒体上露面。Troy博士拥有康奈尔大学工业和劳动关系学士学位，得克萨斯大学奥斯汀分校美国文明硕士和博士学位。
Tevi D. Troy is a Senior Fellow at the Ronald Reagan Institute, Senior Scholar at the Straus Center at Yeshiva University, former White House aide and a best selling author on presidential history. Dr. Troy is former Deputy Secretary of the U.S. Department of Health and Human Services, the chief operating officer of the largest civilian department in the federal government, with a budget of $716 billion and over 67,000 employees. Dr. Troy has extensive White House experience, serving in several high level positions, culminating in his service as Deputy Assistant and then Acting Assistant to the President for Domestic Policy. Dr. Troy has held high level positions on Capitol Hill as well, serving as Policy Director for Senator John Ashcroft, Senior Domestic Policy Adviser and later Domestic Policy Director for the House Policy Committee. In addition to governmental work and health care expertise, Dr. Troy has written over 400 published articles for The New York Times, The Wall Street Journal, The Washington Post, Politico, The Atlantic, and many other publications. He is a frequent television and radio analyst, and has appeared on CNN, C SPAN, Fox News, and The NewsHour, among other outlets. Dr. Troy has a B.S. in Industrial and Labor Relations from Cornell University and an M.A and Ph.D. in American Civilization from the University of Texas at Austin. - 特维·D·特洛伊是罗纳德·里根研究所的高级研究员、叶史瓦大学施特劳斯中心的高级学者、前白宫助手和总统历史上最畅销的作家。特洛伊博士是美国卫生与公众服务部前副部长，联邦政府最大文职部门的首席运营官，预算7160亿美元，雇员超过6.7万人。特洛伊博士拥有丰富的白宫经验，曾担任多个高级职位，最终担任副助理，然后是总统国内政策代理助理。特洛伊博士也曾在国会山担任过高级职务，曾担任参议员约翰·阿什克罗夫特的政策主管，高级国内政策顾问，后来担任众议院政策委员会的国内政策主管。除了政府工作和医疗保健方面的专业知识外，特洛伊博士还为纽约时报、华尔街日报、华盛顿邮报、Politico、大西洋和许多其他出版物撰写了400多篇已发表的文章。他经常担任电视和电台分析师，曾在CNN、C SPAN、福克斯新闻、NewsHour等媒体上露面。Troy博士拥有康奈尔大学工业和劳动关系学士学位，得克萨斯大学奥斯汀分校美国文明硕士和博士学位。
- Tevi D. Troy is a Senior Fellow at the Ronald Reagan Institute, Senior Scholar at the Straus Center at Yeshiva University, former White House aide and a best selling author on presidential history. Dr. Troy is former Deputy Secretary of the U.S. Department of Health and Human Services, the chief operating officer of the largest civilian department in the federal government, with a budget of $716 billion and over 67,000 employees. Dr. Troy has extensive White House experience, serving in several high level positions, culminating in his service as Deputy Assistant and then Acting Assistant to the President for Domestic Policy. Dr. Troy has held high level positions on Capitol Hill as well, serving as Policy Director for Senator John Ashcroft, Senior Domestic Policy Adviser and later Domestic Policy Director for the House Policy Committee. In addition to governmental work and health care expertise, Dr. Troy has written over 400 published articles for The New York Times, The Wall Street Journal, The Washington Post, Politico, The Atlantic, and many other publications. He is a frequent television and radio analyst, and has appeared on CNN, C SPAN, Fox News, and The NewsHour, among other outlets. Dr. Troy has a B.S. in Industrial and Labor Relations from Cornell University and an M.A and Ph.D. in American Civilization from the University of Texas at Austin.
- David Soffer
-
大卫·索弗在科学和医疗保健领域都有杰出的背景。在获得萨斯喀彻温大学生物化学理学学士学位后，Soffer博士是以色列雷霍沃特魏茨曼研究所的一名研究员，在那里，他关于自身免疫性疾病的工作促成了一项发表在《欧洲免疫学杂志》上的研究，题为“主要组织相容性复合体之外的因素影响获得性脑免疫性脑脊髓炎的易感性”。在从事科学工作后，Soffer博士攻读牙科，1996年从萨斯喀彻温大学获得牙科医学博士（DMD）。在接下来的二十年里，他在加拿大农村从事牙科工作，在那里他拥有并经营诊所。他还创立了一个医院牙科项目，在全身麻醉下治疗儿科患者，增强了在服务不足的社区获得护理的机会。Soffer博士继续从事牙科工作，并为需要专门护理的偏远社区提供服务。除了临床工作，Soffer博士还是股市的活跃交易员。
David Soffer has a distinguished background in both science and healthcare. After earning a Bachelor of Science in Biochemistry from the University of Saskatchewan, Dr. Soffer was a researcher at the Weizmann Institute in Rehovot, Israel, where his work on autoimmune disorders led to a published study in the European Journal of Immunology entitled "Factors Outside the Major Histocompatibility Complex Influence Susceptibility to Acquired Autoimmune Encephalomyelitis." Following his scientific work, Dr. Soffer pursued dentistry, graduating with a Doctor of Dental Medicine (DMD) from the University of Saskatchewan in 1996. Over the next two decades, he practiced dentistry in rural Canada, where he owned and operated clinics. He also founded a hospital dentistry program to treat pediatric patients under general anesthesia, enhancing access to care in underserved communities. Dr. Soffer continues to practice dentistry and serve outlying communities that require specialized care. Beyond his clinical work, Dr. Soffer is an active trader in the stock market. - 大卫·索弗在科学和医疗保健领域都有杰出的背景。在获得萨斯喀彻温大学生物化学理学学士学位后，Soffer博士是以色列雷霍沃特魏茨曼研究所的一名研究员，在那里，他关于自身免疫性疾病的工作促成了一项发表在《欧洲免疫学杂志》上的研究，题为“主要组织相容性复合体之外的因素影响获得性脑免疫性脑脊髓炎的易感性”。在从事科学工作后，Soffer博士攻读牙科，1996年从萨斯喀彻温大学获得牙科医学博士（DMD）。在接下来的二十年里，他在加拿大农村从事牙科工作，在那里他拥有并经营诊所。他还创立了一个医院牙科项目，在全身麻醉下治疗儿科患者，增强了在服务不足的社区获得护理的机会。Soffer博士继续从事牙科工作，并为需要专门护理的偏远社区提供服务。除了临床工作，Soffer博士还是股市的活跃交易员。
- David Soffer has a distinguished background in both science and healthcare. After earning a Bachelor of Science in Biochemistry from the University of Saskatchewan, Dr. Soffer was a researcher at the Weizmann Institute in Rehovot, Israel, where his work on autoimmune disorders led to a published study in the European Journal of Immunology entitled "Factors Outside the Major Histocompatibility Complex Influence Susceptibility to Acquired Autoimmune Encephalomyelitis." Following his scientific work, Dr. Soffer pursued dentistry, graduating with a Doctor of Dental Medicine (DMD) from the University of Saskatchewan in 1996. Over the next two decades, he practiced dentistry in rural Canada, where he owned and operated clinics. He also founded a hospital dentistry program to treat pediatric patients under general anesthesia, enhancing access to care in underserved communities. Dr. Soffer continues to practice dentistry and serve outlying communities that require specialized care. Beyond his clinical work, Dr. Soffer is an active trader in the stock market.
高管简历
中英对照 | 中文 | 英文- Sushma Shivaswamy
Sushma Shivaswamy，于2017年11月被任命为公司的首席科学官。作为首席运营官，Shivaswamy博士监督所有与研发和抗体生产良好生产规范相关的科学和技术操作。Shivaswamy博士自2009年以来一直在公司任职，并担任研发总监（2011-2015）和高级科学家（2009-2011）。加入XBiotech之前，Shivaswamy博士是Texas大学奥斯汀分校系统和合成生物学中心的博士后研究员。她拥有细胞和分子生物学中心的分子生物学博士学位。
Sushma Shivaswamy was appointed as the Company's Interim Chief Executive Officer in December 2025 and continues to serve as Chief Scientific Officer. As Interim CEO and CSO, Dr. Shivaswamy oversees all scientific and technical operations with respect to research and development and Good Manufacturing Practice production of antibody. Dr. Shivaswamy has been with the Company since 2009 also holding positions of Director of Research & Development (2011 2015) and Senior Scientist (2009 2011). Prior to joining XBiotech, Dr. Shivaswamy was a postdoctoral researcher at the Center for Systems and Synthetic Biology at the University of Texas at Austin. She has a Ph.D. degree in Molecular Biology from the Center for Cellular and Molecular Biology, India.- Sushma Shivaswamy，于2017年11月被任命为公司的首席科学官。作为首席运营官，Shivaswamy博士监督所有与研发和抗体生产良好生产规范相关的科学和技术操作。Shivaswamy博士自2009年以来一直在公司任职，并担任研发总监（2011-2015）和高级科学家（2009-2011）。加入XBiotech之前，Shivaswamy博士是Texas大学奥斯汀分校系统和合成生物学中心的博士后研究员。她拥有细胞和分子生物学中心的分子生物学博士学位。
- Sushma Shivaswamy was appointed as the Company's Interim Chief Executive Officer in December 2025 and continues to serve as Chief Scientific Officer. As Interim CEO and CSO, Dr. Shivaswamy oversees all scientific and technical operations with respect to research and development and Good Manufacturing Practice production of antibody. Dr. Shivaswamy has been with the Company since 2009 also holding positions of Director of Research & Development (2011 2015) and Senior Scientist (2009 2011). Prior to joining XBiotech, Dr. Shivaswamy was a postdoctoral researcher at the Center for Systems and Synthetic Biology at the University of Texas at Austin. She has a Ph.D. degree in Molecular Biology from the Center for Cellular and Molecular Biology, India.
- Angela Hu
Angela Hu于2015年4月加入XBiotech，最初担任财务总监，后于2023年2月过渡至财务总监职位。胡女士拥有金融学士学位，在加入XBiotech之前曾在美国国家仪器和霍尼韦尔担任高级会计师。
Angela Hu joined XBiotech in April 2015, initially serving as the Financial Controller before transitioning to the position of Director of Finance in February 2023. Ms. Hu holds a bachelor's degree in finance and has previous experience as a senior accountant at National Instruments and Honeywell prior to joining XBiotech.- Angela Hu于2015年4月加入XBiotech，最初担任财务总监，后于2023年2月过渡至财务总监职位。胡女士拥有金融学士学位，在加入XBiotech之前曾在美国国家仪器和霍尼韦尔担任高级会计师。
- Angela Hu joined XBiotech in April 2015, initially serving as the Financial Controller before transitioning to the position of Director of Finance in February 2023. Ms. Hu holds a bachelor's degree in finance and has previous experience as a senior accountant at National Instruments and Honeywell prior to joining XBiotech.